Please provide your email address to receive an email when new articles are posted on . The addition of amivantamab-vmjw to chemotherapy extended PFS among a subset of patients with non-small cell ...
HOUSTON -- Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can ...
Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of ...
Treatment with Opdivo (nivolumab) in combination with the novel therapy BMS-986012 demonstrated a median overall survival of 18.7 months and a median progression-free survival of 2.1 months among a ...
Please provide your email address to receive an email when new articles are posted on . A quarter of patients with unresectable or metastatic angiosarcoma responded to a combination of ipilimumab and ...
HOUSTON ― Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a ...
Hosted on MSN
New approach for testing multiple treatment combinations at once could aid in development of cancer drugs
MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their approach allows scientists to efficiently estimate how combinations of ...
Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) released a study investigating the use of combination checkpoint immunotherapy ...
CURE spoke with Michael J. Overman, M.D. about the promise of anti-PD-1 therapy for patients with MSI-H colorectal cancer. Recent data shows promise for the use of anti-PD-1 therapy in the second-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback